Education
About Us
Working with TipRanks
Follow Us
Brainstorm Cell Therapeutics (BCLI)
NASDAQ:BCLI
RESEARCH TOOLSreports
Top Page
Brainstorm Cell Therapeutics
(NASDAQ:BCLI)
Rating:40Underperform
Price Target:―
Positive Factors
Regulatory Approval
The FDA clearance for the upcoming P3b study in amyotrophic lateral sclerosis positions BrainStorm to acquire funds to conduct the trial, including non-dilutive sources such as a $15M grant and potential strategic partnerships.
Regulatory Environment
Changes to the regulatory landscape seem to support a more favorable environment for NurOwn, with the agency more open to evaluating large datasets and understanding how biomarkers correlate with patient outcomes.
Therapy Development
BrainStorm continues to lead in the development of ALS therapies by demonstrating the impact of NurOwn cells on reduced neuroinflammation and neurodegeneration.
Negative Factors
Biotech Valuations
Valuations across much of the Biotech space have continued to pullback and reset, with reductions in price targets for multiple stocks.
Macroeconomic Factors
Market uncertainty pressures U.S. Biotech stocks, with recession fears and interest rates that remain elevated.
Market Conditions
Difficult market conditions, particularly for small/micro-cap stocks, and economic uncertainty continue to pressure broader markets.
Brainstorm Cell Therapeutics (BCLI) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$8.57M
Dividend YieldN/A
Average Volume (3M)2.23M
Price to Earnings (P/E)―
Beta (1Y)1.70
Revenue GrowthN/A
EPS Growth62.35%
CountryUS
Employees27
SectorHealthcare
Sector Strength41
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.45
Shares Outstanding7,938,876
10 Day Avg. Volume6,381,509
30 Day Avg. Volume2,227,269
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-1.04
Price to Sales (P/S)0.00
P/FCF Ratio-0.60
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$6.00Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Brainstorm Cell Therapeutics Business Overview & Revenue Model
Company DescriptionBrainstorm Cell Therapeutics Inc., a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function. It is developing NurOwn, which has completed Phase III clinical trial for the treatment of amyotrophic lateral sclerosis; and Phase II clinical trial for the treatment of progressive multiple sclerosis and alzheimer's disease, as well as for other neurodegenerative diseases. The company has a partnership with Catalent for manufacturing NurOwn. The company was formerly known as Golden Hand Resources Inc. and changed its name to Brainstorm Cell Therapeutics Inc. in November 2004. Brainstorm Cell Therapeutics Inc. was incorporated in 2000 and is headquartered in New York, New York.
How the Company Makes MoneyBrainstorm Cell Therapeutics generates revenue through the development and commercialization of its proprietary cellular therapies. The company's primary revenue stream is expected to come from the sale or licensing of NurOwn, pending regulatory approval and successful commercialization. Additionally, Brainstorm may engage in strategic partnerships and collaborations with pharmaceutical companies, research institutions, and other stakeholders to advance its clinical programs and expand its market reach. These partnerships may provide upfront payments, milestone payments, and royalties, contributing to the company's earnings. Other potential revenue sources include government grants and funding from non-profit organizations that support research in neurodegenerative diseases.
Brainstorm Cell Therapeutics Financial Statement Overview
Summary
Brainstorm Cell Therapeutics faces significant financial challenges with negative profitability, weak balance sheet stability, and reliance on external financing. The company needs substantial improvements in revenue generation and cost management to enhance its financial health.Income Statement
The company has consistently generated negative net income and EBIT margins, with minimal to no revenue growth over the past years. Despite a small revenue in the TTM period, margins remain negative, indicating ongoing operational challenges.30
Negative
Balance Sheet
The company's balance sheet shows negative stockholders' equity and high liabilities relative to assets, indicating financial instability. The high debt-to-equity ratio further suggests potential insolvency risks.20
Very Negative
Cash Flow
The company has consistently negative operating cash flow, with no positive free cash flow growth. The cash flow from financing indicates reliance on external funding, which may not be sustainable long-term.25
Negative
| Breakdown | |||||
| TTM | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 |
|---|---|---|---|---|---|
| Income Statement | Total Revenue | ||||
| 139.00K | 0.00 | 0.00 | 0.00 | 0.00 | -366.00K | Gross Profit |
| -55.00K | -265.00K | -285.00K | -260.00K | -219.00K | -732.00K | EBIT |
| -13.31M | -21.44M | -24.82M | -24.54M | -31.68M | -23.00M | EBITDA |
| -13.39M | -16.93M | -23.99M | -24.28M | -31.46M | -23.09M | Net Income Common Stockholders |
| -14.23M | -17.19M | -23.73M | -24.38M | -31.94M | -23.50M |
| Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
| 1.22M | 1.30M | 2.98M | 22.09M | 41.94M | 569.00K | Total Assets |
| 1.99M | 4.21M | 8.45M | 29.28M | 51.26M | 6.53M | Total Debt |
| 9.00K | 672.00K | 4.09M | 5.08M | 7.22M | 2.37M | Net Debt |
| -1.21M | -628.00K | 3.32M | -13.78M | -30.61M | 1.83M | Total Liabilities |
| 1.99M | 9.07M | 11.47M | 9.94M | 15.79M | 18.76M | Stockholders Equity |
| 3.00K | -4.86M | -3.02M | 19.34M | 35.46M | -12.22M |
| Cash Flow | Free Cash Flow | ||||
| -11.33M | -20.48K | -19.35M | -26.59M | -35.57M | -11.72M | Operating Cash Flow |
| -11.33M | -20.46M | -19.32M | -26.27M | -35.19M | -11.25M | Investing Cash Flow |
| 196.00K | 2.19M | 998.00K | 323.00K | -4.45M | 5.62M | Financing Cash Flow |
| 10.26M | 18.98M | 238.00K | 6.97M | 76.94M | 5.22M |
Brainstorm Cell Therapeutics Technical Analysis
Negative
1.08
Price Trends
1.18
Negative
1.52
Negative
2.15
Negative
Market Momentum
<0.01
Positive
44.07
Neutral
6.70
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BCLI, the sentiment is Negative. The current price of 1.08 is below the 20-day moving average (MA) of 1.20, below the 50-day MA of 1.18, and below the 200-day MA of 2.15, indicating a bearish trend. The MACD of <0.01 indicates Positive momentum. The RSI at 44.07 is Neutral, neither overbought nor oversold. The STOCH value of 6.70 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BCLI.
Brainstorm Cell Therapeutics Risk Analysis
Brainstorm Cell Therapeutics disclosed 64 risk factors in its most recent earnings report. Brainstorm Cell Therapeutics reported the most risks in the “Tech & Innovation” category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Brainstorm Cell Therapeutics Peers Comparison
Overall Rating
UnderperformOutperform
Sector (53)
Financial Indicators
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
53 Neutral | $5.14B | 3.03 | -44.09% | 2.83% | 16.75% | -0.06% | |
42 Neutral | $6.08M | ― | -195.46% | ― | -29.46% | 2.71% | |
41 Neutral | $6.34M | 49.73 | -18.56% | ― | -100.00% | ― | |
40 Underperform | $8.57M | ― | 234.90% | ― | ― | 62.35% | |
34 Underperform | $7.47M | ― | -538.87% | ― | ― | -26.02% | |
| $7.65M | ― | -302.69% | ― | ― | ― | ||
| $2.63M | ― | ― | ― | ― |
* Healthcare Sector Average
Performance Comparison
BCLI
Brainstorm Cell Therapeutics
1.08
-6.67
-86.06%
GTBP
GT Biopharma
2.89
-0.64
-18.13%
GNPX
Genprex
0.28
-1.84
-86.79%
APM
Aptorum Group
0.89
-4.03
-81.91%
LYRA
Lyra Therapeutics
0.09
-0.24
-72.73%
CDT
Conduit Pharmaceuticals
3.48
-4,541.52
-99.92%
Brainstorm Cell Therapeutics Earnings Call Summary
Earnings Call Date:May 16, 2025
(Q1-2025)
| % Change Since: -6.90%|
Next Earnings Date:Aug 18, 2025
Earnings Call Sentiment Neutral
The earnings call highlighted significant progress in regulatory clearance and clinical trial preparations for NurOwn, alongside promising biomarker research and development in the exosome program. However, financial constraints and the need for funding to initiate the trial were notable challenges.Q1-2025 Updates
Positive Updates
Regulatory Clearance for Phase 3b Trial
The U.S. FDA has cleared Brainstorm Cell Therapeutics to initiate the Phase 3b trial for NurOwn, marking a significant milestone in their ALS treatment development.
Strong Interest from Clinical Sites
Brainstorm is negotiating with approximately 15 leading clinical centers across the United States for their Phase 3b trial, highlighting strong interest and support from renowned ALS clinicians and researchers.
Positive Biomarker Research
Significant changes in biomarkers were observed in the study, showing NurOwn's potential multimodal mechanism of action, including neuroprotective and anti-inflammatory effects.
Exosome Program Progress
Promising preclinical data from Brainstorm's exosome program demonstrates therapeutic effects in models of lung disease, with active pursuit of strategic partnerships for clinical development.
Negative Updates
Financial Constraints and Funding Challenges
Brainstorm faces significant financial constraints, impacting their ability to execute the clinical trial without securing robust and sustainable cash flow.
Reliance on Funding for Trial Initiation
The company acknowledged the necessity to secure adequate funding before commencing the Phase 3b trial, highlighting the financial hurdles faced.
Company Guidance
During the Brainstorm Cell Therapeutics First Quarter 2025 Conference Call, extensive guidance was provided regarding the company's strategic and operational plans. The company announced the U.S. FDA clearance to initiate a pivotal Phase 3b trial for their NurOwn technology, aimed at treating early-stage ALS patients, marking a significant regulatory milestone. Additionally, they plan to initiate manufacturing at the Tel Aviv Sourasky Medical Center, with a subsequent technology transfer to Pluri for expanded cleanroom facilities. The trial, named ENDURANCE, is designed under a Special Protocol Assessment (SPA) with the FDA to mitigate regulatory risks. Approximately 15 leading clinical centers across the U.S. are poised to participate in the trial, with ongoing negotiations for clinical trial agreements. The company also highlighted the financial constraints and ongoing efforts to secure strategic funding, including a $15 million non-dilutive grant under review. These initiatives underscore the company's commitment to developing innovative therapeutic options for ALS within a challenging financial environment.Glossary
OutperformA stock rated as "Outperform" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock is likely to deliver higher returns compared to the average returns of other stocks in the same sector or market index. Investors might consider this stock a good buying opportunity.
NeutralA stock rated as "Neutral" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly attractive nor unattractive for investment. Investors may consider holding onto the stock, as it is not expected to either significantly outperform or underperform the market.
UnderperformA stock rated as "Underperform" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests that the stock may deliver lower returns compared to the average returns of other stocks in the same sector or market index. Investors might consider selling the stock or avoiding it as an investment.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.